Cargando…

NYX‐2925, A Novel N‐methyl‐D‐aspartate Receptor Modulator: A First‐in‐Human, Randomized, Double‐blind Study of Safety and Pharmacokinetics in Adults

NYX‐2925, a new chemical entity, acts as a co‐agonist to glutamate at the N‐methyl‐D‐aspartate receptor (NMDAR). At low concentrations of endogenous agonists (glycine/D‐serine), NYX‐2925 partially activates NMDARs, modulating neural pathways relevant for chronic pain. NYX‐2925 is being developed for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Houck, David R., Sindelar, Laurel, Sanabria, Carlos R., Stanworth, Stephanie H., Krueger, Maggie, Suh, Mary, Madsen, Torsten M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440576/ https://www.ncbi.nlm.nih.gov/pubmed/30242962 http://dx.doi.org/10.1111/cts.12584

Ejemplares similares

NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory
por: Khan, M Amin, et al.
Publicado: (2017)

The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFC
por: Morrison, Gladys, et al.
Publicado: (2019)

NYX‐2925 induces metabotropic N‐methyl‐d‐aspartate receptor (NMDAR) signaling that enhances synaptic NMDAR and α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor
por: Bowers, M. Scott, et al.
Publicado: (2019)

Mutations in NYX of individuals with high myopia, but without night blindness
por: Zhang, Qingjiong, et al.
Publicado: (2007)

Brucella effectors NyxA and NyxB target SENP3 to modulate the subcellular localisation of nucleolar proteins
por: Louche, Arthur, et al.
Publicado: (2023)

Two Novel NYX Gene Mutations in the Chinese Families with X-linked Congenital Stationary Night Blindness
por: Dai, Shuzhen, et al.
Publicado: (2015)

NYX mutations in four families with high myopia with or without CSNB1
por: Zhou, Lin, et al.
Publicado: (2015)

Early Functional and Morphologic Abnormalities in the Diabetic Nyx(nob) Mouse Retina
por: Tarchick, Matthew J., et al.
Publicado: (2016)

Receptive Field Sizes of Nyx(nob) Mouse Retinal Ganglion Cells
por: Hölzel, Maj-Britt, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes
por: Svehlikova, Eva, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People With Type 1 Diabetes
por: Svehlikova, Eva, et al.
Publicado: (2023)

A dataset of the mid-brunhes period at site MD05-2925, Solomon Sea: Surface-subsurface planktonic foraminifera stable C-O isotope and Mg/Ca ratios
por: Lo, Li, et al.
Publicado: (2021)

N-Methyl-D-Aspartate Receptors in Hematopoietic Cells: What Have We Learned?
por: Kalev-Zylinska, Maggie L., et al.
Publicado: (2020)

Conformational Selection and Submillisecond Dynamics of the Ligand-binding Domain of the N-Methyl-d-aspartate Receptor
por: Dolino, Drew M., et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL‐1601D with US and European insulin aspart in healthy volunteers: A randomized, double‐blind, crossover, euglycaemic glucose clamp study
por: Hövelmann, Ulrike, et al.
Publicado: (2021)

2-Methylaspartic acid monohydrate
por: Brewer, Greg, et al.
Publicado: (2013)

Rapid model exploration for complex hierarchical data: application to pharmacokinetics of insulin aspart
por: Goudie, Robert J. B., et al.
Publicado: (2015)

Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial
por: Buse, John B., et al.
Publicado: (2018)

Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
por: Heise, T., et al.
Publicado: (2015)

Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects
por: Shin, Wonsuk, et al.
Publicado: (2020)

Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial
por: Heise, Tim, et al.
Publicado: (2016)

Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist
por: Garner, Rachel, et al.
Publicado: (2015)

Anticonvulsive Effects and Pharmacokinetic Profile of Cannabidiol (CBD) in the Pentylenetetrazol (PTZ) or N-Methyl-D-Aspartate (NMDA) Models of Seizures in Infantile Rats
por: Uttl, Libor, et al.
Publicado: (2021)

Anti-N-methyl-D-aspartate Receptor Encephalitis
por: Tanquary, Gregory, et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Properties of l-Ornithine l-Aspartate (LOLA) in Hepatic Encephalopathy
por: Kircheis, Gerald, et al.
Publicado: (2019)

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016)

The association between anti‐insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast‐acting insulin aspart in children and adolescents with type 1 diabetes
por: Biester, Torben, et al.
Publicado: (2020)

Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia
por: Weickert, C S, et al.
Publicado: (2013)

Pediatric anti-N methyl D aspartate receptor encephalitis
por: Suri, Vinit, et al.
Publicado: (2013)

Pediatric N-Methyl-D-Aspartate Receptor Autoimmune Encephalitis
por: Uvais, N. A.
Publicado: (2018)

Roles of N-Methyl-D-Aspartate Receptors (NMDARs) in Epilepsy
por: Chen, Shuang, et al.
Publicado: (2022)

Protein quality control of N-methyl-D-aspartate receptors
por: Benske, Taylor M., et al.
Publicado: (2022)

Symptomatic treatments of N-methyl-D-aspartate receptor encephalitis
por: Lee, Soon-Tae
Publicado: (2021)

Symptomatologic pathomechanism of N-methyl D-aspartate receptor encephalitis
por: Lee, Woo-Jin
Publicado: (2021)

Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study
por: Oliver, R., et al.
Publicado: (2021)

Selective Vulnerabilities of N-methyl-D-aspartate (NMDA) Receptors During Brain Aging
por: Magnusson, Kathy R., et al.
Publicado: (2010)

Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions
por: Hövelmann, Ulrike, et al.
Publicado: (2017)

Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study
por: Strasser, F, et al.
Publicado: (2008)

Selective Prefrontal Disinhibition in a Roving Auditory Oddball Paradigm Under N-Methyl-D-Aspartate Receptor Blockade
por: Rosch, Richard E., et al.
Publicado: (2019)

Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation
por: Robbie, Gabriel J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4lo52qm70333fuke45qnme91ut